The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis.
Anakinra
Anti-interleukin-1 treatment
Canakinumab
Colchicine resistant
Familial mediterranean fever (FMF)
Multiple sclerosis (MS)
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
29
04
2020
revised:
12
06
2020
accepted:
22
06
2020
pubmed:
10
7
2020
medline:
15
5
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
It has been reported that multiple sclerosis (MS) is more common among patients with familial Mediterranean fever (FMF) than expected in normal population. Also, an association between MEFV gene variants and disease severity in MS has been described. Excessive production of interleukin-1 (IL-1) beta is responsible for FMF pathogenesis, and anti-IL-1 treatment is an effective approach in colchicine-resistant FMF patients. Here, we describe three patients with FMF and coexisting MS who have been treated with anti-IL-1 agents. Our observations suggest that blocking IL-1 is a safe and an effective alternative for colchicine resistant FMF and probably also for associated MS.
Identifiants
pubmed: 32645635
pii: S2211-0348(20)30408-9
doi: 10.1016/j.msard.2020.102332
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
MEFV protein, human
0
Pyrin
0
Colchicine
SML2Y3J35T
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
102332Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.